MedWatch

Oncology Venture has USD 8.7 million deficit after nine months

Biotech company Oncology Venture has significantly increased its deficit in the third quarter, and for the first three quarters as a whole, but the company's finances are comfortable going into 2020, says the new finance director.

Henrik Moltke, finance director at Oncology Venture Photo: PR / Oncology Venture

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles